// App-Quantinova.ai

M5159 2016 AHA : Acute Pharmacological Inhibition of PI3K? by the Novel Cancer Drug, BYL-719, Has a Pro-arrhythmic Effect

Researchers

Presenter

  • Brent McLean

Principal Investigators

  • Bart Vanhaesebroeck

  • Queen Mary

  • Gavin Y. Oudit

Medical Centers

  • Univ. of Alberta, Edmonton, Alberta, Canada.

  • University of Lincoln, Lincoln, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Phosphatidylinositol

  • Ranexa

  • Alpelisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved